Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) have been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $16.50.
Several equities analysts recently commented on the company. BidaskClub upgraded ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. ValuEngine cut ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. HC Wainwright reiterated a “buy” rating and issued a $9.50 price objective on shares of ZIOPHARM Oncology in a report on Tuesday, November 7th. Zacks Investment Research upgraded ZIOPHARM Oncology from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a report on Saturday, January 6th. Finally, Raymond James Financial reiterated a “hold” rating on shares of ZIOPHARM Oncology in a report on Monday, December 11th.
Several institutional investors and hedge funds have recently bought and sold shares of the company. BlackRock Inc. boosted its holdings in shares of ZIOPHARM Oncology by 3.4% in the 4th quarter. BlackRock Inc. now owns 8,499,209 shares of the biotechnology company’s stock worth $35,187,000 after purchasing an additional 280,003 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of ZIOPHARM Oncology by 7.6% in the 2nd quarter. Vanguard Group Inc. now owns 7,864,470 shares of the biotechnology company’s stock worth $48,917,000 after purchasing an additional 553,933 shares in the last quarter. State Street Corp boosted its holdings in shares of ZIOPHARM Oncology by 12.8% in the 2nd quarter. State Street Corp now owns 4,556,264 shares of the biotechnology company’s stock worth $28,342,000 after purchasing an additional 517,057 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of ZIOPHARM Oncology by 10.1% in the 2nd quarter. Northern Trust Corp now owns 1,630,858 shares of the biotechnology company’s stock worth $10,144,000 after purchasing an additional 149,067 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in shares of ZIOPHARM Oncology by 2.0% in the 4th quarter. Geode Capital Management LLC now owns 1,160,653 shares of the biotechnology company’s stock worth $4,805,000 after purchasing an additional 22,575 shares in the last quarter. Hedge funds and other institutional investors own 40.26% of the company’s stock.
ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $3.83 on Friday. ZIOPHARM Oncology has a 52-week low of $3.33 and a 52-week high of $7.88. The company has a market capitalization of $536.71, a PE ratio of -7.37 and a beta of 1.42.
TRADEMARK VIOLATION WARNING: This news story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/18/ziopharm-oncology-inc-ziop-receives-average-recommendation-of-hold-from-brokerages.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.